MedTrace Logo

Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects

NCT06422039 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-29

No results posted yet for this study

Summary

This study was designed as a a single-center, randomized, open, interleaved (3-cycle, 3-sequence) trial. It is planned to enroll 18 healthy subjects.

Conditions

Interventions

DRUG

HRS-7535(D) Tablets

One HRS-7535(D) Tablet is administered to healthy subjects.

DRUG

HRS-7535(C) Tablets

Two HRS-7535(C) Tablets is administered to healthy subjects.

Sponsors & Collaborators

  • Shandong Suncadia Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-23
Primary Completion
2024-08-06
Completion
2024-08-06

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06422039 on ClinicalTrials.gov